Invokana lawsuits allege patients were not properly warned about the risk of diabetic ketoacidosis, a potentially serious situation in which patients develop high level of ketones. Additionally, some patients allege they developed kidney failure as a result of using Invokana. According to some reports, at least 57 separate Invokana lawsuits have been filed in 11 federal districts alleging failure to warn on the part of Janssen. Another 87 lawsuits filed in Philadelphia are under consideration for consolidation in that jurisdiction.
In October, Janssen filed a response to the motion for consolidation, noting that it agreed the lawsuits should be consolidated and transferred to a single court for pretrial proceedings. In its filing, however, Janssen noted the suits should be transferred to a judge with the ability to manage the lawsuits and prevent any abuse of the courts. The company agreed with the proposed move to New Jersey before Judge Brian Martinotti and proposed Judge Amy St. Eve in the Northern District of Illinois as an alternative.
Among arguments in favor of transferring the lawsuit to New Jersey are that Judge Martinotti has already advanced some pending Invokana lawsuits and that 37 of the 57 pending lawsuits were filed in New Jersey, meaning far fewer would have to be transferred to the jurisdiction.
READ MORE INVOKANA LEGAL NEWS
Janssen had tried to have a lawsuit filed in Pennsylvania dismissed, arguing the plaintiff had no ties to Pennsylvania and getting the doctor to testify in Pennsylvania would be problematic. The plaintiff—Matthew Landes—argued because Janssen has offices in Pennsylvania, filing the lawsuit in the city would make evidence collecting more efficient.
Judge Denis P. Cohen refused Janssen's request to dismiss the lawsuit but did not give a reason for the decision.
The proposed New Jersey MDL is In Re: Invokana (Canagliflozin) Products Liability Litigation, MDL 2750.